Acrivon Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Acrivon Therapeutics, Inc. (ACRV) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $1.04 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- Acrivon Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $3.89, a 0.26% increase year-over-year.
- Acrivon Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $3.88, a 122.99% increase year-over-year.
- Acrivon Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $1.74.
- Acrivon Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $3.89, a 33.68% increase from fiscal 2024.
- Acrivon Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $2.91, a 9.81% increase from fiscal 2023.
- Acrivon Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $2.65, a 181.91% increase from fiscal 2022.
- Acrivon Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $0.94.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.04 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $3.89 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $3.89 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $3.89 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | $3.89 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $2.91 10-K · filed 2025-03-27 | |||
| 2024-09-30 | $2.91 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $2.91 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $3.88 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $2.65 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $2.49 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $2.56 10-Q · filed 2023-08-11 | |||
| 2023-03-31 | $1.74 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $0.94 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |